SGYP Synergy Pharmaceuticals Inc.

2.88
-0.15  -5%
Previous Close 3.03
Open 3.01
Price To book 15.16
Market Cap 647870230
Shares 224,954,941
Volume 4,549,072
Short Ratio 11.13
Av. Daily Volume 5,635,948

SEC filingsSee all SEC filings

  1. 8-K - Current report 171070269
  2. 8-K - Current report 171067580
  3. S-8 - Securities to be offered to employees in employee benefit plans 171039014
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018661
  5. 8-K - Current report 171018482

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. PDUFA date January 24, 2018.
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
Approved January 19, 2017.
Trulance (plecanatide)
Chronic idiopathic constipation (CIC)
Phase 1b data released January 2016. Phase 2 planned.
Dolcanatide
Mild-to-moderate ulcerative colitis

Latest News

  1. H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP)
  2. Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)
  3. Synergy Pharmaceuticals to Highlight New Data for TRULANCE® (Plecanatide) at the World Congress of Gastroenterology (WCOG) at American College of Gastroenterology (ACG)
  4. Synergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : October 4, 2017
  5. Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher
  6. Synergy Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SGYP-US : October 3, 2017
  7. See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
  8. Today's Research Reports on Trending Tickers: Synergy Pharmaceuticals and Jaguar Health
  9. Why Synergy Pharmaceuticals Rallied 12% Today
  10. Analysts Take Action on Health Care Stocks
  11. CORRECTING and REPLACING Synergy Pharmaceuticals to Present at Upcoming September Investor Conferences
  12. Edited Transcript of SGYP earnings conference call or presentation 7-Sep-17 8:30pm GMT
  13. Synergy Pharmaceuticals to Present at Upcoming September Investor Conferences
  14. 2017 is a Transformative Year for Synergy, Q2 Review, and Analyst Outlook
  15. Synergy Pharmaceuticals Secures $300 Million Debt Financing
  16. Synergy Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SGYP) : August 12, 2017
  17. Here's Why Synergy Pharmaceuticals Inc. Is Falling Today
  18. IHS Markit Score Update: Drop in demand for ETFs holding Synergy Pharmaceuticals Inc is a negative sign for its shares
  19. Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update

SEC Filings

  1. 8-K - Current report 171070269
  2. 8-K - Current report 171067580
  3. S-8 - Securities to be offered to employees in employee benefit plans 171039014
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018661
  5. 8-K - Current report 171018482
  6. 8-K - Current report 17955779
  7. 8-K - Current report 17933935
  8. 8-K - Current report 17896081
  9. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17888831
  10. 8-K - Current report 17875982